Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2024

Open Access 01-03-2024 | Myocarditis | Research

Germline HAVCR2/TIM-3 Checkpoint Inhibitor Receptor Deficiency in Recurrent Autoinflammatory Myocarditis

Authors: Nora Pernaa, Anni Vakkuri, Miika Arvonen, Outi Kuismin, Wenny Santaniemi, Virpi Glumoff, Elisa Lappi-Blanco, Ulla Lantto, Marjo Okkonen, Kari Kaikkonen, Juhani Junttila, Risto Kerkelä, Pirjo Åström, Timo Hautala

Published in: Journal of Clinical Immunology | Issue 3/2024

Login to get access

Abstract

Myocarditis can be caused by viral infection, drug reaction or general inflammatory condition. To provide understanding on inflammatory myocarditis, we describe clinical, genetic, and immunological properties of a young male patient who suffered from recurrent myocarditis episodes since the age of four years. Electrocardiography, troponin I/T, echocardiography, myocardial magnetic resonance imaging and histological findings were consistent with recurrent myocarditis episodes. Homozygous c.245 A > G p.Tyr82Cys pathogenic variant in Hepatitis A Virus Cellular Receptor 2 (HAVCR2) gene encoding T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) receptor was found. Peripheral blood mononuclear cells were collected when the patient was asymptomatic; CD4+ and CD8+ T lymphoblasts, CD56+ natural killer cells and CD14+ monocytes were negative for surface TIM-3 expression. In vitro, TLR4 mediated interleukin-1β (IL-1β) response was high after LPS/ATP stimulation. Clinical symptoms responded to IL-1 receptor antagonist anakinra. TIM-3 p.Tyr82Cys CD4+ and CD8+ T cell proliferation in vitro was unrestrained. Findings on IL-2, interferon gamma, regulatory T cells, signal transducer and activator of transcription (STAT) 1, 3 and 4 phosphorylation, and PD-1 and LAG-3 checkpoint inhibitor receptor analyses were comparable to controls. We conclude that TIM-3 deficiency due to homozygous HAVCR2 c.245 A > G p.Tyr82Cys pathogenic variant in the patient described here is associated with autoinflammatory symptoms limited to early onset recurrent febrile myocarditis. Excessive IL-1β production and defective regulation of T cell proliferation may contribute to this clinical condition responsive to anakinra treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173–85.CrossRefPubMed Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173–85.CrossRefPubMed
2.
go back to reference Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–41.CrossRefPubMed Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–41.CrossRefPubMed
4.
go back to reference Zhang Y, Zhang M, Li X, Tang Z, He L, Lv K. Expansion of CD11bLy-6 C myeloid-derived suppressor cells (MDSCs) driven by galectin-9 attenuates CVB3-induced myocarditis. Mol Immunol. 2017;83:62–71.CrossRefPubMed Zhang Y, Zhang M, Li X, Tang Z, He L, Lv K. Expansion of CD11bLy-6 C myeloid-derived suppressor cells (MDSCs) driven by galectin-9 attenuates CVB3-induced myocarditis. Mol Immunol. 2017;83:62–71.CrossRefPubMed
5.
go back to reference Gayden T, Sepulveda FE, Khuong-Quang D-A, Pratt J, Valera ET, Garrigue A, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50:1650–7.CrossRefPubMed Gayden T, Sepulveda FE, Khuong-Quang D-A, Pratt J, Valera ET, Garrigue A, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50:1650–7.CrossRefPubMed
6.
go back to reference Tromp SAM, Gillissen MA, Bernelot Moens SJ, van Leeuwen EMM, Jansen MH, Koens L, et al. Treatment of an HLH-mimic disease based on HAVCR2 variants with absent TIM-3 expression. Blood Adv. 2022;6:4501–5.CrossRefPubMedPubMedCentral Tromp SAM, Gillissen MA, Bernelot Moens SJ, van Leeuwen EMM, Jansen MH, Koens L, et al. Treatment of an HLH-mimic disease based on HAVCR2 variants with absent TIM-3 expression. Blood Adv. 2022;6:4501–5.CrossRefPubMedPubMedCentral
7.
go back to reference Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS Phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42:1508–20.CrossRefPubMed Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS Phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42:1508–20.CrossRefPubMed
9.
go back to reference Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18:169–93.CrossRefPubMed Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18:169–93.CrossRefPubMed
10.
go back to reference Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.CrossRefPubMedPubMedCentral Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.CrossRefPubMedPubMedCentral
11.
go back to reference Myocarditis in auto. -immune or auto-inflammatory diseases. Autoimmun Rev. 2017;16:811–6.CrossRef Myocarditis in auto. -immune or auto-inflammatory diseases. Autoimmun Rev. 2017;16:811–6.CrossRef
12.
go back to reference Staels F, Roosens W, Giovannozzi S, Moens L, Bogaert J, Iglesias-Herrero C, et al. Case report: myocarditis in congenital STAT1 gain-of function. Front Immunol. 2023;14:1095595.CrossRefPubMedPubMedCentral Staels F, Roosens W, Giovannozzi S, Moens L, Bogaert J, Iglesias-Herrero C, et al. Case report: myocarditis in congenital STAT1 gain-of function. Front Immunol. 2023;14:1095595.CrossRefPubMedPubMedCentral
14.
go back to reference Wei Q, Sun L. Monogenic autoinflammatory disease-associated cardiac damage. Inflamm Res. 2023;1–5. Wei Q, Sun L. Monogenic autoinflammatory disease-associated cardiac damage. Inflamm Res. 2023;1–5.
15.
go back to reference Baggio C, Gagno G, Porcari A, Paldino A, Artico J, Castrichini M, et al. Myocarditis: which role for Genetics? Curr Cardiol Rep. 2021;23:1–7.CrossRef Baggio C, Gagno G, Porcari A, Paldino A, Artico J, Castrichini M, et al. Myocarditis: which role for Genetics? Curr Cardiol Rep. 2021;23:1–7.CrossRef
16.
go back to reference Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.CrossRefPubMedPubMedCentral Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.CrossRefPubMedPubMedCentral
17.
go back to reference Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-x-linked-like syndrome. J Allergy Clin Immunol. 2013;131:1611–23.CrossRefPubMedPubMedCentral Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-x-linked-like syndrome. J Allergy Clin Immunol. 2013;131:1611–23.CrossRefPubMedPubMedCentral
18.
go back to reference Soy M, Atagündüz P, Atagündüz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int. 2020;41:7–18.CrossRefPubMedPubMedCentral Soy M, Atagündüz P, Atagündüz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int. 2020;41:7–18.CrossRefPubMedPubMedCentral
19.
go back to reference Ng CT, Fong LY, Abdullah MNH. Interferon-gamma (IFN-γ): reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function. Cytokine. 2023;166:156208.CrossRefPubMed Ng CT, Fong LY, Abdullah MNH. Interferon-gamma (IFN-γ): reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function. Cytokine. 2023;166:156208.CrossRefPubMed
20.
21.
go back to reference Ashari KA, Hausmann JS, Dedeoglu F. Update on autoinflammatory diseases. Curr Opin Rheumatol. 2023;35:285–92.CrossRefPubMed Ashari KA, Hausmann JS, Dedeoglu F. Update on autoinflammatory diseases. Curr Opin Rheumatol. 2023;35:285–92.CrossRefPubMed
22.
go back to reference Ou W, Zhao Y, Wei A, Ma H, Zhang L, Lian H, et al. Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature. Clin Exp Med. 2023;23:4575–83.CrossRefPubMed Ou W, Zhao Y, Wei A, Ma H, Zhang L, Lian H, et al. Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature. Clin Exp Med. 2023;23:4575–83.CrossRefPubMed
23.
go back to reference Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic Lymphohistiocytosis. Arch Pathol Lab Med. 2022;146:507–19.CrossRefPubMed Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic Lymphohistiocytosis. Arch Pathol Lab Med. 2022;146:507–19.CrossRefPubMed
25.
go back to reference De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: an Interleukin-1-Mediated Disease? Front Immunol. 2018;9:364763. De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: an Interleukin-1-Mediated Disease? Front Immunol. 2018;9:364763.
26.
go back to reference Van Den Eeckhout B, Tavernier J, Gerlo S. Interleukin-1 as Innate Mediator of T Cell Immunity. Front Immunol. 2021;11:621931.CrossRefPubMed Van Den Eeckhout B, Tavernier J, Gerlo S. Interleukin-1 as Innate Mediator of T Cell Immunity. Front Immunol. 2021;11:621931.CrossRefPubMed
27.
28.
go back to reference Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, et al. Immunomodulating therapies in Acute myocarditis and Recurrent/Acute pericarditis. Front Med. 2022;9:838564.CrossRef Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, et al. Immunomodulating therapies in Acute myocarditis and Recurrent/Acute pericarditis. Front Med. 2022;9:838564.CrossRef
29.
Metadata
Title
Germline HAVCR2/TIM-3 Checkpoint Inhibitor Receptor Deficiency in Recurrent Autoinflammatory Myocarditis
Authors
Nora Pernaa
Anni Vakkuri
Miika Arvonen
Outi Kuismin
Wenny Santaniemi
Virpi Glumoff
Elisa Lappi-Blanco
Ulla Lantto
Marjo Okkonen
Kari Kaikkonen
Juhani Junttila
Risto Kerkelä
Pirjo Åström
Timo Hautala
Publication date
01-03-2024
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2024
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-024-01685-x

Other articles of this Issue 3/2024

Journal of Clinical Immunology 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.